Delivering Next Generation Alzheimer's Treatments:
Connecting Research, Regulation and Access
27-28 October 2016, Lausanne, Switzerland
Stopping Alzheimer's disease by 2025 requires investment, collaboration, and creativity. That is why at the 3rd Lausanne Dialogue 27-28 October 2016 we will take an interdisciplinary approach to discuss the following themes with regulators, researchers, industry representatives, payers, and those living with dementia:
- What are the key challenges facing the regulatory environment from now until 2025 and how can we resolve them?
- How can the evidence be developed to support the payer community?
- What can we learn from other diseases - and how can we apply these learnings to Alzheimer's?
The OECD Working Party on BNCT is at the forefront to advise on how research and innovation in biotechnology, nanotechnology and novel, emerging and converging technologies can contribute to address global challenge of Alzheimer’s disease and other dementias. The Lausanne Dialogue will help keep the momentum of ongoing, global stakeholder action, for example: the UK G8 ‘Dementia Summit’ (2013); OECD work on collaborative research and data sharing; the first Lausanne workshop ‘Enhancing translational research and clinical development for Alzheimer’s disease and other dementias: The way forward’ (2014); and the ‘Ministerial Conference on Global Action Against Dementia’ (2015), organised by the WHO with support from the Department of Health of UK and the OECD. Further details on OECD work on dementia click here.
The Lausanne Dialogue is organised under the auspices of the OECD Working Party on Biotechnology, Nanotechnology, and Converging Technologies (BNCT). It is being hosted by the Government of Switzerland and supported by the Global CEO Initiative on Alzheimer’s Disease and Alzheimer’s Disease International (ADI). Link: Draft Agenda